Ebola primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Ebola}} | {{Ebola}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Vaccines have been produced for both Ebola <ref name="Jones2005">{{cite journal |last=Jones |first=Steven |authorlink= |coauthors=''et al.'' |year=2005 |month= |title=Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses |journal=[[Nature Medicine]] |volume=11 |issue=7 |pages=786-790 |doi=10.1038/nm1258 |url= |accessdate= |quote= }}</ref> and Marburg<ref name="Hevey1998">{{cite journal |last=Hevey |first=M |authorlink= |coauthors=''et al.'' |year=1998 |month= |title=Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates |journal=Virology |volume=251 |issue=1 |pages=28-37 |doi=10.1006/viro.1998.9367 |url= |accessdate= |quote= }}</ref> that were 99% effective in protecting a group of monkeys from the disease. These vaccines are based on either a [[recombinant]] [[Vesicular stomatitis virus]] or a recombinant [[Adenoviridae|Adenovirus]]<ref name="Sullivan2003">{{cite journal |last=Sullivan |first=Nancy |authorlink= |coauthors=''et al.'' |year=2003 |month= |title=Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates |journal=[[Nature (journal)|Nature]] |volume=424 |issue=6949 |pages=681-684 |doi=10.1038/nature01876 |url= |accessdate= |quote= }}</ref> carrying the Ebola spikeprotein on its surface. Early human vaccine efforts, like the one at [[NIAID]] in 2003, have so far not reported any successes.<ref>{{cite press release |title=NIAID Ebola Vaccine Enters Human Trial |publisher=National Institute of Allergy and Infectious Diseases |date=2003-11-18 |url=http://www3.niaid.nih.gov/news/newsreleases/2003/ebolahumantrial.htm |format= |language= |accessdate= |quote= }}</ref> The biggest problem with the vaccine is that unless the patient is given it near the onset of the virus (1-4 days after the symptoms begin) then there will be too much damage to the human body to repair, ie: ruptured [[arteries]] and [[capillaries]], [[vomiting]], and other symptoms which may still cause enough harm to kill or seriously traumatize the patient. | Vaccines have been produced for both Ebola <ref name="Jones2005">{{cite journal |last=Jones |first=Steven |authorlink= |coauthors=''et al.'' |year=2005 |month= |title=Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses |journal=[[Nature Medicine]] |volume=11 |issue=7 |pages=786-790 |doi=10.1038/nm1258 |url= |accessdate= |quote= }}</ref> and Marburg<ref name="Hevey1998">{{cite journal |last=Hevey |first=M |authorlink= |coauthors=''et al.'' |year=1998 |month= |title=Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates |journal=Virology |volume=251 |issue=1 |pages=28-37 |doi=10.1006/viro.1998.9367 |url= |accessdate= |quote= }}</ref> that were 99% effective in protecting a group of monkeys from the disease. These vaccines are based on either a [[recombinant]] [[Vesicular stomatitis virus]] or a recombinant [[Adenoviridae|Adenovirus]]<ref name="Sullivan2003">{{cite journal |last=Sullivan |first=Nancy |authorlink= |coauthors=''et al.'' |year=2003 |month= |title=Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates |journal=[[Nature (journal)|Nature]] |volume=424 |issue=6949 |pages=681-684 |doi=10.1038/nature01876 |url= |accessdate= |quote= }}</ref> carrying the Ebola spikeprotein on its surface. Early human vaccine efforts, like the one at [[NIAID]] in 2003, have so far not reported any successes.<ref>{{cite press release |title=NIAID Ebola Vaccine Enters Human Trial |publisher=National Institute of Allergy and Infectious Diseases |date=2003-11-18 |url=http://www3.niaid.nih.gov/news/newsreleases/2003/ebolahumantrial.htm |format= |language= |accessdate= |quote= }}</ref> The biggest problem with the vaccine is that unless the patient is given it near the onset of the virus (1-4 days after the symptoms begin) then there will be too much damage to the human body to repair, ie: ruptured [[arteries]] and [[capillaries]], [[vomiting]], and other symptoms which may still cause enough harm to kill or seriously traumatize the patient. | ||
| Line 8: | Line 11: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Ebola| ]] | |||
[[Category:Mononegavirales]] | |||
[[Category:Viral diseases]] | |||
[[Category:Biological weapons]] | |||
[[Category:Zoonoses]] | |||
[[Category:Hemorrhagic fevers]] | |||
[[Category:Mature chapter]] | |||
[[Category:Needs content]] | |||
{{WH}} | |||
{{WS}} | |||
Revision as of 21:41, 7 December 2012
|
Ebola Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Postmortem Care |
|
Case Studies |
|
Ebola primary prevention On the Web |
|
American Roentgen Ray Society Images of Ebola primary prevention |
|
Risk calculators and risk factors for Ebola primary prevention |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Vaccines have been produced for both Ebola [1] and Marburg[2] that were 99% effective in protecting a group of monkeys from the disease. These vaccines are based on either a recombinant Vesicular stomatitis virus or a recombinant Adenovirus[3] carrying the Ebola spikeprotein on its surface. Early human vaccine efforts, like the one at NIAID in 2003, have so far not reported any successes.[4] The biggest problem with the vaccine is that unless the patient is given it near the onset of the virus (1-4 days after the symptoms begin) then there will be too much damage to the human body to repair, ie: ruptured arteries and capillaries, vomiting, and other symptoms which may still cause enough harm to kill or seriously traumatize the patient.
References
- ↑ Jones, Steven (2005). "Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses". Nature Medicine. 11 (7): 786–790. doi:10.1038/nm1258. Unknown parameter
|coauthors=ignored (help) - ↑ Hevey, M (1998). "Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates". Virology. 251 (1): 28–37. doi:10.1006/viro.1998.9367. Unknown parameter
|coauthors=ignored (help) - ↑ Sullivan, Nancy (2003). "Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates". Nature. 424 (6949): 681–684. doi:10.1038/nature01876. Unknown parameter
|coauthors=ignored (help) - ↑ "NIAID Ebola Vaccine Enters Human Trial" (Press release). National Institute of Allergy and Infectious Diseases. 2003-11-18.